CTIC Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Jun 2023 @ 15:58):

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States...

Stats
Today's Volume	5.56M
Average Volume	5.66M
Market Cap	1.20B
EPS	$0 ( 2024-03-04 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.84
ATR14	$0.183 (2.01%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-26	Bvf Partners L P/il	Sell	43 139	Common Stock, par value $0.001
2023-06-26	Bvf Partners L P/il	Sell	12	Series X Convertible Preferred Stock
2023-06-26	Bvf Partners L P/il	Sell	17	Series X1 Convertible Preferred Stock
2023-06-26	Bvf Partners L P/il	Sell	120 000	Stock Option (Right to Buy)
2023-06-26	Bvf Partners L P/il	Sell	60 000	Stock Option (Right to Buy)

INSIDER POWER
-81.58
Last 99 transactions
Buy: 2 253 317 \| Sell: 15 023 868

Volume Correlation

Long: 0.20 (neutral)

Short: -0.41 (neutral)

Signal:(83.616) Neutral

CTI Biopharma Corp Correlation

10 Most Positive Correlations
APYX	0.961
DRNA	0.957
DMRC	0.956
EVLV	0.956
IZEA	0.952
BOXL	0.95
CELH	0.947
GT	0.944
GSMG	0.943
ALBO	0.942

10 Most Negative Correlations
ITI	-0.951
MBIN	-0.937
VRCA	-0.928
CPRX	-0.928
AMPH	-0.922
INOD	-0.922
SPPI	-0.921
NVCT	-0.914
SLMBP	-0.914
PMTS	-0.913

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CTI Biopharma Corp Correlation - Currency/Commodity

0.74
( moderate )

0.73
( moderate )

0.57
( weak )

0.58
( weak )

0.21
( neutral )

-0.35
( neutral )

CTI Biopharma Corp Financials

Annual	2022
Revenue:	$53.95M
Gross Profit:	$50.43M (93.49 %)
EPS:	$-0.790

Q1	2023
Revenue:	$24.12M
Gross Profit:	$22.89M (94.92 %)
EPS:	$-0.170

Q4	2022
Revenue:	$21.08M
Gross Profit:	$19.92M (94.46 %)
EPS:	$-0.130

Q3	2022
Revenue:	$18.24M
Gross Profit:	$17.09M (93.68 %)
EPS:	$-0.130

Financial Reports:

No articles found.

CTI Biopharma Corp

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.